Fairmount Funds Management 13F annual report
Fairmount Funds Management is an investment fund managing more than $885 billion ran by Erin O'connor. There are currently 13 companies in Mrs. O'connor’s portfolio. The largest investments include Axsome Therapeutics Inc and Nuvalent Inc, together worth $336 billion.
$885 billion Assets Under Management (AUM)
As of 7th August 2024, Fairmount Funds Management’s top holding is 2,360,077 shares of Axsome Therapeutics Inc currently worth over $190 billion and making up 21.5% of the portfolio value.
Relative to the number of outstanding shares of Axsome Therapeutics Inc, Fairmount Funds Management owns more than approximately 0.1% of the company.
In addition, the fund holds 1,924,626 shares of Nuvalent Inc worth $146 billion.
The third-largest holding is Spyre Therapeutics Inc worth $94.5 billion and the next is Apogee Therapeutics Inc worth $80.6 billion, with 2,048,647 shares owned.
Currently, Fairmount Funds Management's portfolio is worth at least $885 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Fairmount Funds Management
The Fairmount Funds Management office and employees reside in West Conshohocken, Pennsylvania. According to the last 13-F report filed with the SEC, Erin O'connor serves as the Chief Compliance Officer at Fairmount Funds Management.
Recent trades
In the most recent 13F filing, Fairmount Funds Management revealed that it had opened a new position in
Kiniksa Pharmaceuticals Intl and bought 3,204,841 shares worth $59.8 billion.
The investment fund also strengthened its position in Spyre Therapeutics Inc by buying
3,639,680 additional shares.
This makes their stake in Spyre Therapeutics Inc total 4,018,101 shares worth $94.5 billion.
On the other hand, there are companies that Fairmount Funds Management is getting rid of from its portfolio.
Fairmount Funds Management closed its position in Kiniksa Pharmaceuticals International Plc on 14th August 2024.
It sold the previously owned 3,204,841 shares for $63.2 billion.
Erin O'connor also disclosed a decreased stake in Terns Pharmaceuticals Inc by 0.6%.
This leaves the value of the investment at $5.1 billion and 748,996 shares.
One of the average hedge funds
The two most similar investment funds to Fairmount Funds Management are Voya Advisors and Mkp Capital Management, L.L.C. They manage $885 billion and $886 billion respectively.
Erin O'connor investment strategy
Fairmount Funds Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 37.1% of
the total portfolio value.
The fund focuses on investments in the United States as
30.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
approximately 0.1% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.17 billion.
The complete list of Fairmount Funds Management trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Axsome Therapeutics Inc |
No change
2,360,077
|
$189,986,199,000 | 21.46% |
| Nuvalent Inc |
No change
1,924,626
|
$146,002,128,000 | 16.50% |
| Spyre Therapeutics Inc |
961.81%
4,018,101
|
$94,465,555,000 | 10.67% |
| Apogee Therapeutics Inc |
No change
2,048,647
|
$80,614,259,000 | 9.11% |
| Enliven Therapeutics Inc |
No change
3,202,798
|
$74,849,389,000 | 8.46% |
| Dianthus Therapeutics Inc |
No change
2,762,837
|
$71,502,222,000 | 8.08% |
| Kiniksa Pharmaceuticals International Plc. |
Closed
3,204,841
|
$63,231,513,000 | |
| Kiniksa Pharmaceuticals Intl |
Opened
3,204,841
|
$59,834,381,000 | 6.76% |
| Cogent Biosciences, Inc. |
31.74%
6,225,641
|
$52,482,154,000 | 5.93% |
| Astria Therapeutics Inc |
No change
3,554,129
|
$32,342,574,000 | 3.65% |
| Merus N.V |
Closed
717,254
|
$32,297,948,000 | |
| Protagonist Therapeutics Inc |
No change
931,890
|
$32,289,989,000 | 3.65% |
| Viridian Therapeutics Inc |
No change
1,845,813
|
$24,014,027,000 | 2.71% |
| Tyra Biosciences Inc |
Closed
1,393,329
|
$22,850,596,000 | |
| Geron Corp. |
Closed
6,666,667
|
$22,000,001,000 | |
| Bicycle Therapeutics plc |
Opened
1,069,199
|
$21,640,588,000 | 2.44% |
| Terns Pharmaceuticals Inc |
63.28%
748,996
|
$5,100,663,000 | 0.58% |
| No transactions found | |||
| Showing first 500 out of 17 holdings | |||
Hedge funds similar to Fairmount Funds Management
- Mv Capital Management, Inc
- Clough Capital Partners L P
- Kopernik Global Investors
- Pale Fire Capital Se
- Palo Alto Investors L.P.
- Greenbrier Partners Capital Management
- Mkp Capital Management, L.L.C
- Voya Advisors
- Icici Prudential Asset Management Co Ltd
- Quantum Capital Management, Nj
- Crewe Advisors
- Connable Office Inc
- Zweig-dimenna Associates
- Pine Ridge Advisers